Артериальная гипертензия

Расширенный поиск

Клиническое значение гомоцистеинемии (обзор литературы)

Полный текст:

Об авторах

Е. И. Баранова
СПбГМУ им. акад. И.П.Павлова

О. О. Большакова
СПбГМУ им. акад. И.П.Павлова

Список литературы

1. Шевченко O.П., Олефриенко Г.А. Гипергомоцистеинемия и ее клиническое значение.Лаборатория. 2002; 1:3-7-

2. Blacber J, Benetos A, Kirzin J et al. Relation of plasma homocysteine to cardiovascular mortality in a French population. Am J Cardiol 2002; 90 (6): 591 -5.

3. Booth G, Wang E. Preventive health care, 2000 update: screening and management ofhyperhomocysteinemia for the prevention of coronary artery disease events. CMA f2000; 163 (I): 21-9.

4. Bots M, Launer L, Lindemans J et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. The Rotterdam Study. Arch Intern Med 1999; 159:38-44-

5. Brophy J. The edpidemiology of acute myocardial infarction and ischemic heart disease in Canada: data from 1976 to 1991. Can J Cardiol 1997; 13: 74—178.

6. Cappuccio F, Bell R, Perry I et al. Homocysteine levels in men and women of different ethnic and cultural background living in England. Atherosclerosis 2002;164 (I): 95-102.

7. Carey M, Donovan D, FitzGerald O. McAulcy F. Homocystinuria. A ctinical and pathological study of nine subjects in six families. AmJ Med 1968; 45: 7-25.

8. Chen C, Surowiec S'. Morsy A, Ma M. Intraperitoneal infusion of homocysteine increases intimai hyperplasia in balloon-injured rat carotid arteries. Atherosclerosis 2002; 160 (I): 103-14-

9. Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:114-55·

10. Coppola A, Davi G, De Stefano V et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin Tbromb Hemost 2000; 26:243-54.

11. Den HeiJer M, Koster T, Blom H et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334 (12): 759-62.

12. Falcon C, Cattaneo M. Panzeri D et al. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14:1080-3.

13. Fu W, Dudman N, Perry M, Wang X. Homocysteinemia attenuates hemodynamic responses to nitric oxide in vivo. Atherosclerosis 2002; 161 (I): 169-76.

14. Genser D. Homocysteine, vitamins, and restenosis after percutaneous coronary intervention. Cardiovasc Rev Rep 2003; 24 (5): 253-8.

15. Graham M, Daly L, Refsum H et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted actionproject.JAMA 1997; 277 (22): 1775-81.

16. Grubben M, Boers G, Blom H et al. Unfiltered coffee increases plasma homocysteine concentration in healthy volunteers: a randomized trial. Am J ClinNutr 1997; 71 (2): 480-4.

17. Hainaut PJaumotte C, Verhelst D et at. Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res 2002; 106 (2): 121-5·

18. Hak E, Bak A, Lindemans J et al. The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled study. Atherosclerosis 2001; 158 (2): 437-43.

19. Hansram М, Gillespie J, Stansby G. Homocysteine in myointimal hyperplasia. EurJ Vasc Endovasc Surg 2002; 23:3-10.

20. Harker L, Ross R, Slichter S, Scott C. Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974; 291:537-43-

21. Hoffman M, Kohl B, Zumbach M et al. Hyperhomocyst(e)inemia and endothelial dysfunction in 1DDM. Diabetes Care 1998; 21:841-8.

22. Janson J, Galarza C, Muraa A et al. Prevalence of hyperhomocysteinemia in an elderly population. AmJ Hypertens 2002; 15 (I): 394-7.

23. Kahleová R, Palyzova D, Zvara K et al. Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypetens 2002; 15 (10): 857-64.

24. Kanani P, Sinkey C, Browning R et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 1999; 100:1161-8.

25. Kark J, Selhub J, Adler B et al. Nonfasting plasma total homocysteine level and mortality in middle-aged arid elderly men and women in Jerusalem.Ann Int Med 1999; 131 (5): 321-30.

26. Kaye J, Stanton K, McCann W, Vasikaran S. Homocysteine,folate, MTGFR genotype and vascular morbidity in diabetic subjects. Clin Sci 2002; 102:263-

27. Kuch B, Bobak M, FobkerM et al. Association between homocysteine and coagulation factors - a cross-sectional study in two populations of Central Ewope. Atherosclerosis 2001; 103 (4): 265-73-

28. Lim S, Kim M, Park K et al. Correlation of plasma homocysteine and mytochondrial DNA content in peripheral blood of healthy women. Atherosclerosis 2001; 158 (2): 399-405-

29. Loscalo J. The oxidant stress of hyperhomocyst(e)inemia.J Clin Invest 1996; 98 (I):5-7.

30. Mager Ą Battler A, Birnbaum Y et al. Plasma homocysteine, methylenetetrahy-drofolate reductase genotype, and age at onset of symptoms of myocardial ischemia. Atheroscterosis 2002; 89 (8): 919-23.

31. Marcucci R, Prisco D, Brunelli T et al. Tissue factor and homocysteine levels in ischemic heart disease are associated with angiogrpbicaüy documented clinical recurrences after coronary angioplasty. Thtvmb Haemost2000; 83:826-32.

32. Mayer EJacobsen D, Robinson K Homocysteine and coronary atherosclerosis. JAm Coll Cardiol 1996; 27:517-27.

33. McCuUy K Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. AmJ Pathol 1969; 56:111-28.

34. McCully K Chemical pathology of homocysteine. Atberogenesis. Anal Clin Lab Sci 1993; 23:477-93.

35. Merki-Feld G, lmthum B, KeUer P. Effects of oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism. Metabolism 2002; 51 (9): 1216-21.

36. Moghadasian M, McManus B, Fröhlich J. Homocysteine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med 1997; 157:2299-308.

37. Moreno H, Kuffaty J, Croce N et al. Homocysteinemia and its relation with risk factor for arterial hypertension. Am J Hypertens 2002; 15 (4, suppl. I ): P.A218.

38. Morita H, Kurihara H, Sugfyama T et al. Polymorphism of the methionine synthase gene. Association with homocysteine metabolism and late-onset vascular disease in the Japanese population. Arterioscler Thromb VascBiol 1999; 19: 298-302.

39. Morita H, Taguchi J, Kurihara H et al. Genetic polymorphism of 5,10-methyl· enetetrahydrofolate reductase as a risk factor for coronary artery disease. Circulation 1997;95:2032-6.

40. Ou T, Yamakawa-Kobayashi K. Arinami T et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphism are independent riskfactors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998; 137:23-8.

41. Rees M, Rodgers G. Homocysteinemia: association of a metabolic disorders with vascular disease and thrombosis. Thromb Res 1993; 71:337-59-

42. Reyes-Engel Ą, Morel M, Aranda F et al. Plasma homocysteine levels, C667T polymorphism of metbylenetetrahydrofalate reductasa gene, plasma renin activity and cardiovascular risk. AmJ Hypertens 2002; I4 (4,suppl. I): P.AÎ54·

43. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345 (22): 1593-600.

44. Schnyder G,Roffi M, Flammer Yet al. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur HeartJ2002; 23: 726-33.

45. Stampfer M, Malinow M. Can lowering homocysteine levels reduce cardiovascular risk? N EnglJ Med 1995; 332:328-9.

46. Stampfer M, Malinow M, WiUettWet alA prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992%;268: 877-81.

47. Stein J, Mc Bride P. Hyperhomocysteinemia and atherosclerotic vascular disease. Arch Intern Med 1998; 158: 1301-6.

48. Tawakol Ą Omland T1 Gerhard M et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependant vasodilatation in humans. Curculation 1997;95:1119-21.

49. Tawakol Ą Forgione M, Stuehlinger M et al. Homocysteine impairs coronary mierovascular dilatorjunction in humans.JACC 2002; 40 (6): 1051

50. Van der Griend R, Haas F, Duran M et al. Methionine loading test is necessary for detection of hyperhomocysteinemia J Lab ClinMed 1996; 132 ( I): 67-72.

51. Veerkamp M, de GraafJ, den HeijerM et al. Plasma homocysteine in subjects withfamilial combined by perlipidetnia. 2003; 166 (I): 111-7.

52. Wald N, Watt H, Law Meta L Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7. '

53. Wang X, Duarte N, Cai H et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-basespopulation. Atherosclerosis 1999; 146:133-40.

54. Warren C. Emergent cardiovascular risk factor: Homocysteine. Prog Cardio-vascNurs 2002; 17-35—41.

55. Welch G, Loscalo J. Homocysteine and atherosclerosis. New EnglJ Med 1998; 338 (15): 1042-50.

56. Welch G, Upchurch G, Loscalo J. Hyperbomoceyst(e)inemia and atherothrombosis. Ann NYAcad Sci 1997; 811:48-58.

57. Wotherspoon F, Laight D, Shaw K, Cummings M. Homocysteine, endothelial dysfunction and oxidative stress in type I diabetes mellitus. BrJ Diabetes Vasc Dis 2003; 3 (5): 334-40.

Для цитирования:

Баранова Е.И., Большакова О.О. Клиническое значение гомоцистеинемии (обзор литературы). Артериальная гипертензия. 2004;10(1):12-15.

For citation:

Baranova Y.I., Bolshakova O.O. Clinical value of homocysteinemia (a review of literature). "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2004;10(1):12-15. (In Russ.)

Просмотров: 132

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)